|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase II mulitcenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck显示文摘 | Baselga J Trigo JM Bourhis J | 2005 | J Clin Oncol2005，23，： | 1 |
| 2 | Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum based agent显示文摘 | Baselga J Trigo JM Bourthis J | 2002 | Proc Am Soc Clin Oncol2002，21，22： | 1 |
| 3 | Tyrosine kinase inhibitors anddrug interactions : a review with practical recommendations 显示文摘 | Pajares B Torres E Trigo JM | 2012 | Clin Transl Oncol2012，14，： | 1 |
| 4 | Phase Ⅱ multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck显示文摘 | Baselga J Trigo JM Bourhis J | 2005 | J Clin Oncol2005，23，24： | 1 |
| 5 | A multicenter phase Ⅱ trial of ZD6474,a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor,in patients with previously treated metastatic breast cancer显示文摘 | Miller KD Trigo JM Wheeler C | | 0，，09： | 1 |
| 6 | Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma:a phase 2 study ( SOGUG-02-06 ) 显示文摘 | Belhnunt J Trigo JM Calvo E | 2010 | Lancet Oncol2010，11，4： | 1 |
| 7 | Seom clini- cal guidelines for the treatment of non-small-cell lung cancer: An updated edition显示文摘 | Trigo Perez JM Garrido Lopez P Felip Font E | 2010 | Clin Transl Oncol2010，12，11： | 1 |
| 8 | Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations 显示文摘 | Pajares B Torres E Trigo JM | 2012 | Clin Transl Oncol2012，14，： | 1 |
| 9 | Discharge profi les of abducens,accessory abducens,and orbicularis oculi motoneurons during reflex and conditioned blinks in alert cats显示文摘 | Trigo JA Gruart A Delgado-Garcia JM | | 0，，： | 1 |
| 10 | A multicenter phase Ⅱ trial of ZD6474, a vascular endothelial growth factor receptor - 2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer显示文摘 | Miller KD Trigo JM Wheeler C | 2005 | Clin Cancer Res2005，11，： | 1 |
| 11 | A multicenter phase Ⅱ trial of Vandetanib,a vascμLar endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor,in patients with previously treated metastatic breast cancer显示文摘 | Miller KD Trigo JM Wheeter C | | 0，，： | 1 |
| 12 | SEOM clinical guidelines for the treatment of non-small-cell lung cancer:an updated edition显示文摘 | Trigo Pérez JM Garrido López P Felip Font E | 2010 | Clin Transl Oncol2010，12，11： | 1 |
| 13 | Cetuximab(C225)plus cisplatin/carboplatin is active in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing on a same dose and schedual platinum-based regimen显示文摘 | Trigo JM Bourhis J | 2001 | Proc Am Soc Clin Oncol2001，21，： | 1 |
| 14 | A multicenter phase Utrial of ZD6474,a vascular endothelial growth factor receptor and epidermal growt h factor receptor tyrosine kinase inhibitor,in patients with previously treated metastatic breast cancer显示文摘 | Miler KD Trigo JM Wheeler C | 2005 | Clin Cancer Res2005，65，11： | 1 |
| 15 | A multicenter phase U trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer显示文摘 | Miler KD Trigo JM Wheeler C | 2005 | Clin Cancer Res2005，11，： | 1 |
| 16 | A muhicenter phase Ⅱ trial of ZD6474, a vascular endothelial growth factor re- ceptor-2 and epidermal growth factor receptor tyrosine kinase in- hibitor, in patients with previously treated Metastatic breast canc- er 显示文摘 | MILLER KD TRIGO JM WHEELER C | 2005 | Clin Cancer Res2005，11，9： | 1 |
| 17 | Phase Ⅱ multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum based chemotherapy in patients with platinum refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck显示文摘 | Baselga J Trigo JM Bourhis J | 2005 | J Clin Oncol2005，23，24： | 1 |
| 18 | Phase Ⅱ muhicenterstudy of the antiepidermal growth factor receptor monoclonalantibody cetuximab in combination with platinumbasedche-motherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck 显示文摘 | BASELGA J TRIGO JM BOURHIS J | 2005 | J Clin Oncol2005，23，24： | 1 |
| 19 | Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck显示文摘 | Baselga J Trigo JM Bourhis J | 2005 | J Clin Oncol2005，23，24： | 1 |
| 20 | Activity of a multitargeted chemo-switch regimen (sorafenib,gemcitabine,and metronomic capecitabine) in metastatic renal-cell carcinoma:a phase 2 study (SOGUG-02-06)显示文摘 | Bellmunt J Trigo JM Calvo E | 2010 | Lancet Oncol2010，11，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员